Nuclear p63 expression in osteoblastic tumors

Area of Science:

• Oncology
• Bone Tumors
• Immunohistochemistry

Background:

• p63 protein expression is noted in osteoblast-precursor cells of giant cell tumors of the bone.
• Limited studies have explored p63 expression in osteoblastic tumors.
• Osteosarcoma and osteoblastoma are bone tumors with osteoblastic differentiation.

Purpose of the Study:

• To investigate p63 as a potential marker for osteoblastic differentiation in osteosarcomas.
• To evaluate p63 as a differential diagnostic marker between osteoblastoma and osteosarcoma.

Main Methods:

• Immunohistochemical staining for p63 was performed on tissue microarrays and whole sections.
• Samples included 71 chemotherapy-naive osteosarcoma biopsy samples, 21 whole osteosarcoma sections, and 8 osteoblastomas.

Main Results:

• Nuclear p63 was detected in 7 of 8 osteoblastomas, primarily in stromal cells of immature areas.
• p63 was positive in 10% of osteosarcoma biopsy samples and 33% of whole osteosarcoma sections.
• p63 expression was observed in both benign osteoblastomas and malignant osteosarcomas.

Conclusions:

• p63 expression in both osteoblastoma and osteosarcoma limits its utility in differentiating between these bone tumors.
• p63 is not a reliable marker for osteoblastic differentiation in skeletal sarcomas due to its low prevalence in osteosarcoma.